Cilofexor
Sponsors
Gilead Sciences
Conditions
Compensated CirrhosisNonalcoholic SteatohepatitisNonalcoholic Steatohepatitis (NASH)Primary Biliary CholangitisPrimary Sclerosing CholangitisPrimary Sclerosing Cholangitis (PSC)
Phase 1
Study in Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GS-9674 (Cilofexor), and the Effect of Food on GS-9674 Pharmacokinetics and Pharmacodynamics
CompletedNCT02654002
Start: 2016-01-20End: 2016-07-14Updated: 2020-10-12
Pharmacokinetics and Pharmacodynamics of Cilofexor in Adults With Normal and Impaired Hepatic Function
CompletedNCT02808312
Start: 2016-07-13End: 2018-10-16Updated: 2021-01-07
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
TerminatedNCT04060147
Start: 2019-10-17End: 2021-09-02Updated: 2023-07-27
Phase 2
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Biliary Cholangitis Without Cirrhosis
TerminatedNCT02943447
Start: 2016-12-01End: 2019-09-04Updated: 2020-09-22
Study to Evaluate the Safety, Tolerability, and Efficacy of Cilofexor in Adults With Primary Sclerosing Cholangitis Without Cirrhosis
CompletedNCT02943460
Start: 2016-11-29End: 2020-05-18Updated: 2021-06-07
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Participants With Nonalcoholic Steatohepatitis (NASH)
CompletedNCT03987074
Start: 2019-07-29End: 2020-07-13Updated: 2021-07-15